Focus On Cancer
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
- Autor: Vários
- Narrador: Vários
- Editora: Podcast
- Mais informações
Informações:
Sinopse
FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer who have been treated with two or more chemotherapies. Released May 17, 2017
